Bright Minds Biosciences (DRUG) said Tuesday that its BMB-101 showed a complete elimination of drop attacks in the DBA/2 mouse model of epilepsy.
"Notably, BMB-101 achieved 100% survival in the DBA/2 model, reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest," Jan Torleif Pedersen, the company's chief science officer, said.
The company said the findings demonstrate the potential of BMB-101 to address critical gaps in the prevention of sudden unexpected death in epilepsy.
Shares of Bright Minds Biosciences rose more than 11% in recent trading.
Price: 36.43, Change: +3.81, Percent Change: +11.68
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。